Reducing Diabetes Burden in Medtronic's Automated Insulin Delivery Systems
Authors' conclusion
MiniMed™ 780G with G4S use was associated with significant reduction in diabetes management burden with fewer closed-loop exits, fingersticks and other interactions, and improvements in glycemic control when compared to the MiniMed™ 670G with GS3.
Study context
- Population
- Adults and children in 3-month pivotal trials (MM670G+GS3: 104 adults, 125 children; MM780G+G4S: 67 adults, 109 children); US real-world users transitioning from MM770G+GS3 to MM780G+G4Splus real-world data (RWD) N = 3851 · MM770G+GS3 to MM780G+G4S 3,851
- Comparison
- MM780G with G4S vs MM670G with GS3
- Outcome
- Diabetes burden metric (pentagon composite metric), change vs MM670G
Methodological detailstwo 3-month pivotal trials compared, real-world data from US users
- Two 3-month pivotal trials compared
- Real-world data from US users
Main finding
As reported in the abstract
Adults: diabetes burden metric change vs MM670G
−22.8%
Children: diabetes burden metric change vs MM670G
−28.5%
Further findings
TIR, change vs MM670G
- Adults
- +3.1% (P = 0.035)
- Children
- +6.4% (P < 0.001)
TBR, change vs MM670G
- Adults
- −1.8% (P < 0.001)
- Children
- −0.7% (P < 0.001)
Mean sensor glucose
- Children: reduction
- −8.6 mg/dL (P < 0.001)
- Adults: no change
Closed-loop use
- Adults
- +17.1% (P < 0.001)
- Children
- +20.5% (P < 0.001)
Closed-loop exits (reduced to about 1 per week)
- Adults
- −0.5 (P < 0.001)
- Children
- −0.7 (P < 0.001)
Fingerstick tests
- Adults
- −6.2 (P < 0.001)
- Children
- −6.9 (P < 0.001)
US real-world data
- Similar outcomes were observed from U.S. RWD
Original publication
Reducing Diabetes Burden in Medtronic's Automated Insulin Delivery Systems. Diabetes Technol Ther. Published 5 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →